Roche to share important oncology data at European Cancer Congress (ECC)

European Cancer Congress (ECC)

Roche to share important oncology data at European Cancer Congress (ECC)

• Data for established therapies Avastin, Herceptin, Kadcyla and Zelboraf amongst highlights
  
• Promising data for the company’s investigational anti-PD-L1 antibody, MEK inhibitor cobimetinib and ALK inhibitor alectinib will also be presented
  
• The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche’s alectinib based on data that will be presented at ECC
  
  

  Avastin: Interfering with the tumour blood supply

  Avastin (bevacizumab) precisely targets VEGF (vascular endothelial growth factor), an early and persistent promoter of tumour angiogenesis, for continued tumour control. At ECC, more than 66 abstracts of Avastin will be presented across several different cancers. Presentation highlights include:
  
• Final overall survival outcomes will be presented from two phase III studies of Avastin in ovarian cancer in ECC Presidential Session II (ICON7 in previously untreated patients and AURELIA for platinum-resistant recurrent ovarian cancer ......